Exosomal Long Non-Coding RNA Expression from Serum of Patients with Acute Minor Stroke
Authors Xu X, Zhuang C, Chen L
Received 9 September 2019
Accepted for publication 23 December 2019
Published 13 January 2020 Volume 2020:16 Pages 153—160
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Yuping Ning
Xiaonan Xu, 1,* Chengle Zhuang, 2,* Liming Chen 1
1Department of Neurology, Shenzhen University General Hospital, Shenzhen 518000, Guangdong Province, People’s Republic of China; 2Department of Urology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Liming Chen Email firstname.lastname@example.org
Background: Acute minor stroke (AMS) is one kind of hypoxic ischemic necrosis with no more than 4 National Institutes of Health Stroke Scale (NIHSS) score. However, the early diagnosis of AMS is tough for lack of effective molecular markers. Recently, many long non-coding RNAs (lncRNAs) associated with AMS have been gradually revealed. Here, we aim to find the potential biomarkers of lncRNAs in exosomes isolated from blood serum of patients with AMS for early detection.
Methods: RNA-seq technique, KEGG pathway analysis and GO enrichment analysis were used in this study. Besides, reverse transcription real-time quantitative polymerase chain reaction (RT-qPCR) was used to validate expression levels of four of eleven differentially expressed lncRNAs (lnc-CRKL-2, lnc-NTRK3-4, RPS6KA2-AS1 and lnc-CALM1-7) involved in the neurotrophin signaling pathway.
Results: The expression levels of lnc-CRKL-2 (mean value 48, standard deviation 4.583, P = 0.003) and lnc-NTRK3-4 (mean value 32.3, standard deviation 2.08, P = 0.001) were increased significantly in AMS patients, while the expression levels of RPS6KA2-AS1 (mean value − 118.7, standard deviation 7.09, P = 0.001) and lnc-CALM1-7 (mean value − 148.7, standard deviation 6.10, P = 0.001) were decreased dramatically.
Conclusion: In conclusion, these four new revealed lncRNAs may be used as novel joint biomarkers for the early detection of AMS.
Keywords: exosomes, stroke, LncRNAs, biomarker
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]